


FORM PTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER UAB-16102/22	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.5) 10/009972	
INTERNATIONAL APPLICATION NO. PCT/US00/40165		INTERNATIONAL FILING DATE 8 JUNE 2000		PRIORITY DATE CLAIMED 8 JUNE 1999	
TITLE OF INVENTION HERPES SIMPLEX VIRUS EXPRESSING FOREIGN GENES AND METHOD FOR TREATING CANCERS THEREWITH					
APPLICANT(S) FOR DO/EO/US WHITLEY, Richard J.; MARKERT, James Mac Dowell; GILLESPIE, George Yancey; PARKER, Jacqueline, Ness					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below. 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 					
Items 13 to 20 below concern document(s) or information included:					
<ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail 23. <input checked="" type="checkbox"/> Other items or information: 					
<p>Written Opinion Amendment Under Rules 66.3 and 66.8 postcard</p>					
				 25006 PATENT TRADEMARK OFFICE	

U.S. APPLICATION NO. (IF KNOWN) SEE 37 CFR 1.5) 10/009972	INTERNATIONAL APPLICATION NO. PCT/US00/40165	ATTORNEY'S DOCKET NUMBER UAB-16102/22
---	--	---

24. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **\$1040.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **\$890.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$740.00**
- ☒ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$710.00**
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) **\$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$710.00

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	15 - 20 =	0	x \$18.00
Independent claims	2 - 3 =	0	x \$84.00
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>

\$0.00

\$0.00

\$0.00

TOTAL OF ABOVE CALCULATIONS =

\$710.00

☒ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

\$355.00

SUBTOTAL =

\$355.00

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

TOTAL NATIONAL FEE =

\$355.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

\$0.00

TOTAL FEES ENCLOSED =

\$355.00

Amount to be: refunded	\$
charged	\$

- ☒ A check in the amount of **\$355.00** to cover the above fees is enclosed.
- ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **07-1180** A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Ellen S. Cogen
Gifford, Krass, Groh, Sprinkle,
Anderson & Citkowski, P.C.
280 N. Old Woodward Avenue, Ste. 400
Birmingham, MI 48009-5394
(248) 647-6000

Ellen S. Cogen
SIGNATURE

Ellen S. Cogen

NAME

38,109

REGISTRATION NUMBER

12/10/01
DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: UAB Research Foundation

Int'l Application No.: PCT/US00/40165

Filed: 08 June 2000

Title: HERPES SIMPLEX VIRUS EXPRESSING FOREIGN GENES AND METHOD
FOR TREATING CANCERS THEREWITH

AMENDMENT UNDER RULES 66.3 AND 66.8

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Sir:

Pages 25-26 are being submitted containing claims 1-15. The status of these claims
are as follows:

Claim 1 has been amended for clarity and to clearly define over the art of
record.

Claim 9 has been amended to clearly define over the art of record.

The remaining claims are unchanged.

Claims 1-15 were held to lack novelty under PCT Article 33(2) as being anticipated
by Toda, et al. Toda, et al. is cited as teaching intratumoral administration of a replication
competent HSV encoding IL-12 wherein the HSV comprises a deletion in the $\gamma_{134.5}$ gene.
Toda, et al. are further cited as teaching antitumoral activity wherein the cancer vaccine
comprising the HSV comprising a deletion in the $\gamma_{134.5}$ gene further comprises a
heterodimeric cytokine IL-12, comprising 35kDa (p35) and 40kDa (p40) subunits.

Claim 1 includes a step of "administering to a subject a therapeutically effective amount of a herpes simplex virus (HSV) comprising a nucleic acid sequence encoding an agent ... such that a direct anti-cancer response is induced in the subject." (claim 1, lines 3-7)

A method of claim 1 of the present invention includes administration of a vector having a "primary characteristic of direct tumor cell oncolysis..." (p.5, line 4) In contrast, Toda, et al. describe an indirect method of affecting cancer cells, using herpes simplex virus (HSV) comprising a nucleic acid sequence encoding IL-12 as an "in situ cancer vaccine" that "... induces a tumor-specific immune response ..." (Toda, et al., p. 4457, 2nd column, lines 12-14). Since the vaccination method of Toda, et al. necessarily involves cells other than the tumor cells, specifically immune cells, in an anti-cancer treatment, it is by definition indirect. The method of the present invention, in contrast, directly affects tumor cells to effect treatment. On the basis of the amendment and these arguments, it is submitted that independent claim 1 is novel over Toda, et al. under PCT Article 33(2). Likewise, it is submitted that claims 2-8 which depend therefrom are not anticipated by Toda, et al.

Claim 9 includes a "nucleic acid sequence encoding for ... IL-12, ...operatively linked to a mammalian promoter..." (claim 9, lines 2-4) In contrast, Toda, et al. describe a herpes simplex virus comprising a nucleic acid sequence "... with the CMV promoter driving IL-12." (Toda, et al., p. 4457, 2nd column, lines 24-25) Toda et al. further describe the viral promoter as preferred since "... expression is strong but transient." (Toda, et al., p. 4457, 2nd column, lines 24-25) On the basis of the amendment and these arguments, it is submitted that independent claim 9 is novel over Toda, et al. under PCT Article 33(2). Likewise, it is submitted that claims 10-15 which depend therefrom are not anticipated by Toda, et al.

It is now believed that all the claims define novelty and inventive step over the prior art. If the Examiner finds to the contrary, it is respectfully requested that the undersigned in

charge of this application be called at the telephone number given below in order to resolve any remaining issues.

Respectfully submitted,

Ellen S. Cogen

Ellen S. Cogen, Reg. No. 38,109
Gifford, Krass, Groh, Sprinkle,
Anderson & Citkowski, P.C.
280 N. Old Woodward Ave., Suite 400
Birmingham, MI 48009-5394
(248) 647-6000

Dated: October 1, 2007

Claims

1 1. A method for treating a subject suffering from cancer, said
2 method comprising the step of:

3 administering to a subject a therapeutically effective amount of a herpes
4 simplex virus (HSV) comprising a nucleic acid sequence encoding for an agent
5 selected from the group consisting of interleukin-12, granulocyte macrophage
6 colony stimulating factor, and cytosine deaminase such that a direct anti-cancer
7 response is induced in the subject.

1 2. A method according to claim 1, wherein said administering step
2 comprises intratumorally disposing the HSV into the subject.

1 3. A method according to claim 1, wherein the HSV vector is
2 substantially aneurovirulent.

1 4. A method according to claim 3, wherein the HSV vector is
2 replication competent.

1 5. A method according to claim 3, wherein the HSV vector
2 comprises a deletion of the $\gamma_134.5$ gene.

1 6. A method according to claim 5, wherein IL-12 genes are
2 inserted within the $\gamma_134.5$ gene deletion.

1 7. A method according to claim 6, wherein the IL-12 genes
2 comprise subunits p35 and p40 separated by an IRES sequence.

1 8. A method according to claim 7, wherein said IL-12 encoding
2 nucleic acid sequence bicistronically expresses the p35 and p40 subunits to
3 produce self-assembling, heterodimeric IL-12 in the HSV vector.

1 9. An anti-tumor pharmaceutical composition comprising a herpes
2 simplex virus (HSV) vector comprising a nucleic acid sequence encoding for a
3 compound selected from the group consisting of IL-12 operatively linked to a
4 mammalian promoter, GM-CSF operatively linked to a promoter, and CD
5 operatively linked to a promoter; and a pharmaceutically acceptable carrier.

1 10. A pharmaceutical composition according to claim 9, wherein
2 said HSV vector is substantially aneurovirulent.

1 11. A pharmaceutical composition according to claim 9, wherein
2 said HSV vector is replication competent.

1 12. A pharmaceutical composition according to claim 9, wherein
2 said HSV vector has been transformed with an expression cassette comprising
3 nucleic acid sequences encoding for the p40 and p35 of IL-12, said subunits
4 being separated from each other by an IRES encoding sequence.

10/009972

J005 Rec'd PCT 10 DEC 2007

Attorney Docket No. UAB-16152/22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: UAB Research Foundation

Int'l Application No.: PCT/US00/40165

Filed: 08 June 2000

Title: HERPES SIMPLEX VIRUS EXPRESSING FOREIGN GENES AND METHOD
FOR TREATING CANCERS THEREWITH

STATEMENT

Assistant Commissioner for Patents
Attn: Box PCT
Washington, D.C. 20231

Dear Sir:

Applicant submits that the amendments being made are to further clarify the case and the appended claims.

It is desired to note that the claimed subject matter is novel and can be shown to comprise an inventive step, evidence of which Applicants reserve the right to make of record in due course of the prosecution.

The above amendment does not go beyond the disclosure in the international application as filed.

Respectfully submitted,

Ellen S. Cogen

Ellen S. Cogen, Reg. No. 38,109
Gifford, Krass, Groh, Sprinkle,
Anderson & Citkowski, P.C.
280 N. Old Woodward Ave., Suite 400
Birmingham, MI 48009-5394
(248) 647-6000

Dated: October 1, 2007

**HERPES SIMPLEX VIRUS EXPRESSING FOREIGN GENES
AND METHOD FOR TREATING CANCERS THEREWITH**

Grant Reference

The research carried out in connection with this invention was supported under a contract (NO1-AI-62554) with the Antiviral Research Branch of the National Institute of Allergy and Infectious Diseases (NIAID), Program Project Grants (PO1 AI 24009; PO1 CA 71933), and the National Institute for Neurologic Disorders and Stroke Mentored Clinical Scientist Development Award (1K08NS01942).

Field of the Invention

The present invention generally relates to modified herpes simplex virus (HSV) vectors and their use for the treatment of tumors. In particular, the present invention relates to HSV expressing a foreign gene such as interleukin 12, granulocyte macrophage colony stimulating factor (GM-CSF), or cytosine deaminase (CD) and a method for treating cancers therewith.

Background of the Invention

Eradication of malignancies arising in the brain has proven to be a formidable task. As an example, gliomas, the most common primary brain tumor, are almost always fatal despite aggressive surgical resection, radiotherapy and chemotherapy; the overall five year survival rate for glioblastoma (GBM), the most malignant glioma, is less than 5.5% and the median survival is approximately one year.

Because of poor survival of patients with GBM and other brain malignancies, novel therapeutic approaches, most notably viral and gene

therapy, have been investigated (for reviews, see Markert et al. (1999) *Rev. Med. Virology* in press; Cobbs et al. (1999) *Persp. Neurolog. Surg.* in press; Andreansky et al. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 11313-11318). The efficacy of using neuroattenuated replication-competent herpes simplex viruses (HSV) for treatment of primary brain tumors is known. These viruses typically contain one or more mutations within the viral genome, including thymidine kinase (tk) (Martuza et al. (1991) *Science* **252**, 854-856), ribonucleotide reductase (Mineta et al. (1995) *Num. Gene Ther.* **1**, 938-943; Kramm et al. (1997) *Hum. Gene Ther.* **8**, 2057-2068), UTPase (Pyles et al. (1997) *Hum. Gene Ther.* **8**, 533-544) or $\gamma_{134.5}$ (Markert et al. (1993) *Neurosurg.* **32**, 597-603; Chambers et al. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 1411-1415). Moderate increases in long-term survival for engineered HSV-treated versus untreated animals have been reported in both syngeneic and xenogeneic murine tumor models of GBM (Markert et al. (2000) *Rev. Med. Virology* **10**, 17-30; Martuza et al. (1991) *Science* **252**, 854-856; Markert et al. (1993) *Neurosurg.* **32**, 597-603; Chambers et al. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 1411-1415; Mineta et al. (1994) *Gene Ther.* **1 Suppl 1**:S78, S78; Andreansky et al. (1997) *Cancer Res.* **57**, 1502-1509; Andreansky et al. (1998) *Gene Ther.* **5**, 121-130; Kaplitt et al. (1994) *J. Neuro-Onc.* **6**, 137-147; Yazaki et al. (1995) *Cancer Res.* **55**, 4752-4756). In addition, Phase I studies in humans with malignant glioma suggest that a multiply mutated HSV (G207) at doses up to 3×10^9 pfu is safe for intracranial inoculation (Markert, JM; Medlock, MD; Rabkin SD; Gillespie, GY; Feigenbaum, F; Hunter, WD; Todo, T; Tornatore, C; and Martuza, RL, unpublished data.

Despite these advantages, it seems likely that multiple modalities of therapy will be necessary to eradicate malignant tumors of the central nervous system (CNS) as well as those originating outside the brain. To increase the efficacy of anti-neoplastic therapy, Applicants studied conditionally replicating $\gamma_134.5^-$ mutants as vectors for gene therapy. These vectors retain direct oncolytic effects for tumor cells, and, additionally, express foreign genes designed to augment their anti-tumor effects. Initially, conditionally replicating mutants expressing interleukin 4 (IL-4) and IL-10 were studied (Andreansky et al. (1998) *Gene Ther.* 5, 121-130). These viruses were evaluated in an orthotopic model of murine glioblastoma utilizing syngeneic GL-261 tumors implanted into immunocompetent C57BL/6 mice. In this model, treatment with IL-4 expressing HSV increased survival over treatment with HSV alone, suggesting that cytokine gene therapy may mediate enhanced tumor-specific killing. IL-4 gene therapy has been shown to enhance anti-glioma effects in several gene therapy models (Okada et al. (1999) *Gene Ther.* 6, 219-226; Wei et al. (1998) *J. Neurovirol.* 4, 237-241; Benedetti et al. (1997) *Num. Gene Ther.* 8, 1345-1353). Such effects are T_H -2-mediated and have been attributed to $CD4^+$ lymphocytes and other effector cells such as eosinophils (Tseng et al. (1997) *J. Immunother.* 20, 334-342). While IL-4 was effective in these animal models, generation of a T_H -1 response, including induction of a memory response against tumor cells, need to have a more durable anti-tumor effect.

Therefore, Applicants constructed a virus expressing a cytokine with increased potential for a tumor-specific response. Interleukin-12 (IL-12) is a

cytokine with potent anti-tumor properties. It is produced by antigen-presenting cells including B lymphocytes, dendritic cells, and monocytes and acts to enhance the cytolytic activity of natural killer (NK) and cytotoxic T lymphocytes (CTL) and the development of a T_H-1-type immune response (Caruso et al. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 11302-11306; Bramson et al. (1996) *Num. Gene Ther.* **7**, 1995-2002; Kishima et al. (1998) *Brit. J. of Cancer* **78**, 446-453; Meko et al. (1996) *Surgery* **120**, 274-283; Nishimura et al. (1996) *Ann. NY Acad. Sci.* **795**, 375-378; Tahara et al. (1995) *Num. Gene Ther.* **6**, 1607-1624; Tahara et al. (1995) *Gene Ther.* **2**, 96-106). IL-12 also possesses anti-angiogenic properties, which may represent a second potential mechanism for its anti-tumor activity (Majewski et al. (1996) *J. Invest. Derm.* **106**, 1114-1118; Kerbel et al. (1995) *J. Natl. Cancer Inst.* **87**, 557-586). IL-12 has been demonstrated to produce anti-glioma immune activity in two different rodent models (Toda et al. (1998) *J. Immunol.* **160**, 4457-4464; Kikuchi et al. (1999) *Cancer Let.* **135**, 47-51). While experimental models utilizing IL-12 for gene therapy have been promising, none have utilized IL-12 expressed from a replication-competent vector (Caruso et al. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 11302-11306; Toda et al. (1998) *J. Immunol.* **160**, 4457-4464; Rakhmilevich et al. (1997) *Num. Gene Ther.* **8**, 1303-1311; Bramson et al. (1996) *Num. Gene Ther.* **7**, 333-342; Tahara et al. (1995) *J. Immunol.* **154**, 6466-6474; Myers et al. (1998) *Laryngoscope* **108**, 261-268). Notably, Phase I human studies utilizing systemic IL-12 therapy have demonstrated toxicity of this cytokine, presumably due to its pleiotrophic effects (Marshall et al. (1995) *Science* 1555).

Applicants have developed a conditionally replication-competent, $\gamma_134.5^-$ mutant, which expresses murine IL-12 (M002), for treatment of brain tumors that retains its ability to replicate in murine tumor cells, maintains its primary characteristic of direct tumor cell oncolysis, produces IL-12 at physiologically relevant amounts, allows for direct expression of the cytokine within the tumor cells after inoculation, increases survival of A/J mice, a murine strain more sensitive to HSV infection, implanted with a syngeneic immunocompetent clone of Neuro2A neuroblastoma tumor cells (median = 52 days) after treatment with M002 versus treatment with the non-cytokine expressing parent virus, R3659 (median = 24 days), and which significantly increases immune-related inflammatory infiltration by CD4⁺ T cells, macrophages and to a lesser extent, CD8⁺ cells in M002-treated tumors versus R3659-treated tumors in brain tissue.

Applicants have also developed conditionally replication competent, $\gamma_134.5^-$ mutants, which express murine GM-CSF (M004) and bacterial CD (M012) for treatment of brain tumors and other cancers.

There exists a need for an anti-tumor therapy, specifically for the treatment of tumors of the central nervous system such as brain tumors and other tumors originating outside the brain with cytokines, that overcomes the problems and disadvantages of previous therapies. The present invention fulfills this long-standing need in the art.

Summary of the Invention

A method for treating a subject suffering from cancer includes administering a therapeutically effective amount of a herpes simplex virus

(HSV) vector expressing a cytokine or other anti-cancer agent encoding nucleic acid sequence, such as coding for interleukin-12, into a subject inducing an anti-tumor response in the subject.

An anti-tumor pharmaceutical composition comprising a herpes simplex virus (HSV) vector comprising a nucleic acid sequence encoding for a compound selected from IL-12, GM-CSF, and CD operatively linked to a promoter, and a pharmaceutically acceptable carrier.

Brief Description of the Drawings

The following detailed description is best understood with reference to the following drawings in which:

Figure 1. Schematic representation of mIL12-expressing HSV (M002). Line 1 illustrates the HSV-1 (F) Δ 305 genome, which contains a 501 bp deletion within the tk gene, as indicated by the Δ symbol. U_L and U_S represent the unique long and unique short sequences, respectively. The inverted repeat sequences are indicated by a , b , and c , with subscripts n and m representing variable numbers of a sequences. Line 2 shows the sequence arrangement of the recombinant HSV R3659. The BstEII-StuI fragment within the γ_1 34.5 gene was replaced by the chimeric α 27-tk gene in the inverted sequences ab (shown above) and $b'a'$ (not shown) flanking the U_L sequence. Line 3 shows the sequence arrangements of the relevant regions in the recombinant mIL12-expressing HSV M001 (tk-) or M002 (tk+). NcoI restriction sites are indicated.

Figure 2. Southern blot hybridization confirming presence of mIL-12 in M002. Viral DNAs were isolated, digested with NcoI, electrophoretically separated, and Southern blot hybridization performed as described in Materials

and Methods. The predicted fragment sizes for each viral DNA (1.76 kb for HSV-1 (F), 0.7 kb for R3659, and 2.2 kb for M002) are indicated by arrows. The 1.6 kb, 0.52 kb and all smaller bands of the 1 kb DNA ladder (Life Technologies) will also hybridize to the probe, which has the same vector backbone as the ladder.

Figure 3. In vitro replication of M001 in human glioma cells. Replicating monolayers of U251MG (top) or D54MG (bottom) human malignant glioma cell lines were infected at 1 pfu/cell with either HSV-1 (F) (closed diamonds), R3659 (closed circles) or M001 (open circles). Replicate cultures were harvested at 12, 24, 48 and 72 hours post-infection and virus titers determined on Vero cell monolayers.

Figure 4. Survival of A/J strain mice with intracerebral Neuro-2A neuroblastomas treated with M002. Neuro-2A cells ($1 \times 10^4/5 \mu\text{l}$) were injected intracerebrally in A/J mice. Five days later, intracerebral tumors were injected with $10 \mu\text{l}$ of saline or 2×10^7 pfu of HSV R3659 or HSV M002 and mouse survivals were monitored. Median survival for saline-treated mice was 19.8 days versus 50.5 days for M002 treated mice ($p = 0.002$), and 19.5 days for HSV R3659-treated mice. Histologic examination of the brains of survivors killed at 59 days revealed no persistent tumor.

Figure 5. Immunohistologic identification of inflammatory cell infiltrates. A/J female mice were injected intracerebrally with Neuro-2A cells ($1 \times 10^5/5 \mu\text{l}$) and five days later were injected intratumorally with 1×10^7 pfu of HSV R3659 (Panels A, C, E, G) or HSV M002 (Panels B, D, F, H). Six days later, the mice were killed and their brains removed intact and embedded in

OCT for preparation of frozen sections. Serial 10 μ -thick sections were reacted with rat monoclonal antibodies to CD4⁺ (Panels A, B) or CD8⁺ T (Panels C, D) cells or macrophages (Panels E, F) and antibody binding detected using horseradish peroxidase-labeled anti-rat antibody and sections were counterstained with Mayer's hematoxylin. Hematoxylin-eosin stained adjacent sections were also shown (Panels G, H).

Figure 6 is a schematic representation of GM-CSF-expressing HSV (M004).

Figure 7 is a schematic representation of cytosine deaminase-expressing HSV (M012).

Detailed Description of the Invention

It has now been found according to the present invention that malignant cancer cells can be treated with a genetically manipulated and/or modified herpes simplex virus, preferably type 1, (HSV-1) expressing a foreign gene, preferably an interleukin 12 (IL-12) gene in order to produce IL-12 constitutively with a target cell and can be used as an effective anti-tumor treatment. The engineered HSV-1 expressing IL-12 can also be used for the treatment of primary and metastatic central nervous system (CNS) tumors including, but not limited to meningiomas, pituitary adenomas, and acoustic neuromas, and specifically brain tumors including glioblastoma, malignant glioma, and low-grade glioma, either with or without cognate therapies such as chemotherapy and/or radiation therapy. Additionally, the engineered HSV-1 expressing IL-12 can be utilized in the treatment of non-CNS tumors including malignant melanoma, hepatocellular carcinoma, head and neck cancers, etc.,

both with and without cognate therapy. The engineered HSV-1 expressing IL-12 can also be utilized as a vaccine or vaccine adjuvant and also for the treatment of infectious diseases by stimulating the immune system.

The engineered HSV-1 vectors express a foreign gene including cytokines such as IL-12, granulocyte macrophage colony stimulating factor (GM-CSF), IL-16, IL-10, IL-4, or cytosine deaminase (CD) and are constructed by inserting the foreign gene, such as a gene encoding for cytokine or other anti-tumor/anti-cancer gene product, into the viral genome of HSV-1. The foreign gene is inserted into a region under the control of promoter-regulatory regions of the viral genome. Thus, the viral genome becomes a vector for the expression of the foreign gene in target cells (e.g., tumor cells). In the present invention, a nucleic acid sequence encoding for IL-12 (see Figure 1) or some other anti-tumor/anti-cancer agent is placed under the transcriptional control of the murine early-growth response-1 promoter (Egr-1). It should be noted that while description is given herein for use of HSV-1 which is readily available to those of ordinary skill in the art, other herpes simplex viruses including HSV-2 can also be utilized in the present invention. See Figure 6 for an HSV-1 vector expressing GM-CSF and see Figure 7 for an HSV-1 vector expressing cytosine deaminase.

The HSV of the present invention is preferably a neuroattenuated, replication-competent HSV. The HSV-1 of the present invention includes a deletion in the $\gamma_134.5$ gene rendering the virus aneurovirulent.

As described below in the Experimental Section, biologically active murine IL-12 consists of heterodimer of the p40 and p35 subunits. The nucleic

acid sequences encoding for the expression of the p35 and p40 subunits are separated by an internal ribosome entry site (IRES) and are inserted as a single expression cassette into HSV to form a recombinant HSV of the present invention. The HSV expresses the murine IL-12 via bicistronic expression of the p35 and p40 subunits separated by the IRES sequence. The IL-12 produced thereby is a self-assembling, heterodimeric, functionally active molecule in HSV-1. The cytokine can then exit the HSV and contact bystander cells and/or elicit and/or enhance the patient's or subject's immune response.

For the engineered HSV vector expressing GM-CSF it was shown by ELISA that significant production of GM-CSF was achieved in Vero cells and in the Neuro2A neuroblastoma cell line of A/J mouse origin. Neurotoxicity studies performed in highly sensitive A/J strain mice revealed that the GM-CSF virus was somewhat toxic at high doses, with an LD₅₀ of approximately 5x10⁶ pfu. Intracranial studies demonstrated increased host survival in an intracranial syngeneic neuroblastoma murine model over mock-treated mice, although treatment with the GM-CSF virus at highest doses demonstrated toxicity.

For the engineered HSV vector expressing cytosine deaminase, cytosine deaminase activity was demonstrated *in vitro* by conversion of tritiated 5-fluorocytosine (5FC) to 5-fluorouracil (5FU). CD-expressing virus has been injected into U87MG human glioma cells intracranially xenografted into *scid* mice and 5FC was administered. The local expression of cytosine deaminase led to very localized tissue metabolism of drugs such as 5-fluorocytosine providing a local anti-tumor effect.

The present invention provides an anti-cancer or anti-neoplasm pharmaceutical agent or composition which constitutively produces IL-12, GM-CSF or CD and, optionally, includes a pharmaceutically acceptable carrier or diluent. The anti-tumor agent according to the present invention can be administered by any number of means and routes known in the art. For example, administration may be by subcutaneous, intravenous, intrathecal, intraventricular, intra-arterial, intramuscular, or intraperitoneal injection, by infusion, or preferably, by direct intratumoral injection. The dosage administered will be dependent upon the condition of the patient and the severity of the disease. Anti-tumor compositions comprising 10^4 to 10^9 virus, preferably 10^7 to 10^8 virus, at a dose, are administered to a patient according to the invention. The treatment can comprise several doses at spaced apart intervals, according to the necessity.

The recombinant HSV expressing IL-12 or other anti-cancer/anti-tumor agent according to the invention will be used in a method for the treatment of a patient or subject suffering from cancer, e.g., a malignant solid tumor, lymphoma or leukemia. The method of treatment includes the step of administering a therapeutically effective amount of an HSV vector expressing an IL-12 or other anti-cancer product encoding nucleic acid sequence into a patient or subject such that an anti-tumor response is induced in the subject.

The terms "patient" and/or "subject" as used herein mean all animals including humans. Examples of patients and/or subjects include humans, rodents, and monkeys.

A "therapeutically effective amount" is an amount of a HSV vector expressing IL-12 or other anti-tumor/cancer agent, that when administered to a patient or subject, inhibits tumor growth, causes tumor regression, prevents metastasis or spread of the tumor, prolongs the survival of the subject or patient, and combinations thereof.

The anti-tumor agents of the present invention can be administered to a patient or subject either alone or as part of a pharmaceutical composition of the agents admixed with a pharmaceutically acceptable carrier, diluent, or excipient.

A preferred route of administration is direct, intratumoral injection. Compositions suitable for injection may comprise physiological acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions, or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be controlled by addition of any of various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic

acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

5 The invention will now be illustrated by the following examples without limiting thereto. In the examples the following Experimental Methods were employed:

Experimental

Materials and Methods

10 *Cells.* Vero cells (American Type Culture Collection [ATTC], Rockville, MD) were grown and maintained in Minimal Essential Medium (Cellgro, Mediatech) containing 7% fetal bovine serum. The human 143 thymidine kinase minus cells (143tk-, ATCC) were grown in Dulbecco's modified Eagle's medium (DMEM) (Cellgro) supplemented with 10% fetal
15 bovine serum. Rabbit skin cells (originally acquired from Dr. J. McClaren, University of New Mexico, Albuquerque, NM, USA) were maintained in DMEM supplemented with 5% fetal bovine serum. The human malignant glioma cell lines U251MG and D54MG were obtained from D.D. Bigner (Duke University, Durham, NC, USA) while the murine neuroblastoma cell
20 line Neuro-2A (derived from strain A/J mice) was purchased from the ATCC (CCL 131, passage 171). These latter three cell lines were maintained in a 50:50 mixture of DMEM and Ham's Nutrient Mixture F-12 (DMEM/F12) supplemented to 2.6 mM L-glutamine and 7% FBS.

Plasmids and viruses. HSV-1 (F) strain is a low passage clinical isolate used as the prototype HSV-1 strain in our series (Post et al. (1981) *Cell* **25**, 227-232; Jenkins et al. (1986) *J. Virol.* **59**, 494-9). Viruses R3616 and R4009, which contain a 1 kb deletion and a stop codon, respectively, within both copies of the $\gamma_134.5$ gene, have been described previously (Chou et al. (1990) *Science* **250**, 1262-1266). Construction of M002, which expresses murine interleukin 12 (mIL-12) under the transcriptional control of the murine early-growth response-1 promoter (Egr-1), is described below. This strategy is identical to that used to construct the cytokine-expressing viruses R8306 (mIL-4) and R8308 (mIL-10) (Andreansky et al. (1998) *Gene Ther.* **5**, 121-130). The plasmids containing the p40 and p35 subunits of mIL-12 in pBluescript-SK+ (Stratagene) (Schoenhaut et al. (1992) *J. Immunol.* **148**, 3433-3440), were kindly provided by Dr. Ueli Gubler (Hoffman-LaRoche, Inc., Nutley, NJ, USA). The p40 subunit was removed by digestion with HindIII (5' end) and BamHI (3' end) and the p35 subunit was removed by digestion with NcoI (5' end) and EcoRI (3' end). The internal ribosome entry site, or IRES, sequence was amplified from vector pCITE-4a+ (Novagen, Madison, WI) using polymerase chain reaction (PCR) and primers 5'-CITE (5'-CGCGGATCCTTATTTTCCACCATATTGCC-3'), which has a BamHI site, and 3'-CITE (5'-GGAGCCATGGATTATCATCGTGTGTTTTTC-3'), which has an NcoI site that retains the translational start sequence. Plasmid pBS-IL12 was constructed by three-way ligation of the murine p40, murine p35 and IRES sequences into HindIII and EcoRI sites of pBS-SK+ such that the IRES sequence separates the p40 and p35 coding sequences. This effectively

duplicates a strategy previously reported for expression of the mIL-12 subunits (Tahara et al. (1995) *J. Immunol.* **154**, 6466-6474). The IL-12 genes were entirely sequenced by the University of Alabama at Birmingham Cancer Center DNA Sequencing Facility.

5 The HSV shuttle plasmid pRB4878 has been previously described (Andreansky et al. (1998) *Gene Ther.* **5**, 121-130). Plasmid 4878-IL12 was constructed as follows: pBS-mIL-12 was digested with XhoI and SpeI to remove a 2.2 kb fragment containing the entire IL-12 subunit coding regions, including the IRES, ends filled in using the Klenow fragment, and ligated into
10 a blunted KpnI site located between the Egr-1 promoter and hepatitis B virus polyA sequences within pRB4878. M001 (tk-) and M002 (tk repaired at native locus) were constructed via homologous recombination as described previously (Andreansky et al. (1998) *Gene Ther.* **5**, 121-130). Two tk-repaired viruses M002.29 and M002.211, were confirmed by Southern blot hybridization of
15 restriction enzyme-digested viral DNAs which were electrophoretically separated on a 1% agarose, 1X TPE gel and transferred to a Zeta-Probe membrane (Bio-Rad). The blot was hybridized with the appropriate DNA probe labeled with alkaline phosphatase using the Gene Images AlkPhos Direct DNA labeling system (Amersham-Pharmacia Biotech, Piscataway, NJ). IL-12
20 production was demonstrated by enzyme-linked immunosorbent assay (ELISA).

ELISA. Production of murine IL-12 by M002 was confirmed and quantified using a murine p70 ELISA kit (R&D Systems, Minneapolis, MN). Briefly, six well plates were seeded at a confluency of 4×10^5 cells/well one day

prior to infection with M002 or control virus at a multiplicity of infection (M.O.I.) = 1 in a total volume of 0.5 ml. After two hours, the inoculum was removed, 1 ml of growth medium was overlaid onto infected wells and plates incubated 24 hr at 37°C. The supernatant was removed, transferred to
5 microcentrifuge tubes, and spun down briefly to remove cellular debris. Either undiluted or 10-fold dilutions of supernatants were analyzed by ELISA, according to the manufacturer's protocol. Experiments were performed at least three separate times to determine average level of cytokine production.

In vitro characterization of M001/M002. In vitro replication of M001
10 in subconfluent cultures of the human malignant glioma cell lines U251MG and D54MG was determined, as previously described (Andreansky et al. (1998) *Gene Ther.* 5, 121-130), at 12, 24, 48 and 72 hours post-infection (hpi). For cytotoxicity assays, monolayers U251MG and D54MG cells, as well as the murine neuroblastoma cell line Neuro-2A were infected with M002.29 and
15 M002.211 at an M.O.I. = 1. The TD₅₀ was determined by alamarBlue™ assay, as described (Andreansky et al. (1997) *Cancer Res.* 57, 1502-1509). Dye conversion values were obtained by reading plates on a Bio-Tek EL310 plate reader (Winooski, VT) with the O.D. value at 590 nm subtracted from the O.D. at 562 nm. The decrease in O.D. relative to uninfected cells was plotted
20 against number of virus plaque forming units (pfu)/ml to determine the number of pfu needed to produce a 50% reduction in O.D.

Animals. Specific pathogen-free female A/J strain mice were obtained from Charles River Laboratories and used at approximately eight weeks of age. All animal studies were conducted in accordance with guidelines for animal

use and care established by The University of Alabama at Birmingham Animal Resource Program and the Institutional Animal Care and Use Committee (IACUC protocol 97K03985).

In vivo characterization of M002. For determination of M002 neurovirulence in A/J strain mice, graded numbers of virus pfu were prepared in sterile milk and 5 µl of each dilution were inoculated into the right cerebral hemisphere of 3-10 mice as described (Chambers et al. (1995) *Proc. Natl. Acad. Sci. USA* 92, 1411-1415). For survival studies, A/J strain mice were stereotactically inoculated with 10^5 Neuro-2A cells in the right cerebral hemisphere. Five days later, mice were randomly divided into three cohorts and 5×10^6 pfu of M002, R3659 or vehicle were stereotactically inoculated into each tumor. Mice were assessed daily; moribund mice were sacrificed and the date of death recorded as described (Chambers et al. (1995) *Proc. Natl. Acad. Sci. USA* 92, 1411-1415).

Histopathology. Three sets of three mice each were injected with Neuro-2A, then treated with M002, R3659 or vehicle as described in the survival experiment. At days three and seven, one mouse from each group was sacrificed and its brain harvested and frozen in Tissue-Tek OCT compound. Sections 10-12 microns thick were cut through the injection site in each brain and mounted on TEPSA-coated slides, fixed in 95% ethanol and blocked in PBS-2% BSA. Sections were stained with standard hemotoxylin and eosin to determine degree of residual tumor, presence of neurotoxicity and extent of any inflammatory response. To characterize the nature of the inflammatory infiltrate, serial sections were reacted with rat monoclonal antibodies specific

for mouse CD4, CD8, and macrophage markers and the antibody binding detected using biotinylated rabbit anti-rat Ig followed successively with an avidin-biotin-horseradish peroxidase complex and 1% diaminobenzidine (Andreansky et al. (1998) *Gene Ther.* 5, 121-130).

Results

Construction of a recombinant HSV-1 expressing murine IL-12.

Previously, work by Applicants demonstrated that recombinant HSV which express murine interleukin-4 (IL-4) could significantly improve survival when injected into tumors implanted in brains of immunocompetent mice in a syngeneic murine model (Andreansky et al. (1998) *Gene Ther.* 5, 121-130). To extend these initial studies, Applicants evaluated recombinant HSV that would express the well-described anti-tumor cytokine IL-12.

Biologically active mIL-12 consists of a heterodimer of the p40 and p35 subunits. Therefore, recombinant HSV M001(tk-) and M002 (tk+) were constructed to express both mIL-12 subunits within a single expression cassette, separated by the internal ribosome entry site (IRES) from the 5' untranslated region of equine encephalomyocarditis virus (Figure 1). Recombinant virus M001 was obtained by co-transfection of plasmid DNAs with R3659 viral DNA and selection of tk(-) viruses on 143tk- cells overlaid with medium containing 100 µg/ml bromodeoxyuridine. The recombinant tk(-) mIL-12-expressing virus M001 was confirmed by Southern blot hybridization (data not shown). Recombinant virus M002 was obtained by cotransfection of M001 viral DNA with pRB4867, a plasmid used to repair the 501 bp deletion within the tk gene in its native locus (U_L23), and subsequent selection in HAT

medium. These recombinant viruses contain two copies of the IL-12 construct replacing both copies of the $\gamma_134.5$ gene. To confirm the presence of the mIL-12 insert in M002, viral DNAs were isolated, digested with NcoI, and evaluated by Southern blot hybridization as described in Materials and Methods and shown in Figure 2. Repair of the tk gene was also verified by hybridization to a probe specific for the tk gene insert (data not shown).

Expression of mIL-12 by M002. To determine if M002 expressed physiologically relevant levels of murine IL-12, culture supernates from M002- or R3659-infected Vero and Neuro2A cells were quantified using a commercially available ELISA kit specific for mIL-12 p70 heterodimers. Applicants evaluated IL-12 production from two genetically identical subclones of M002, clone 29 and clone 211. The averaged values are indicated in Table 1. The highest production of mIL-12 by M002 was seen in Vero and Neuro-2A cells, which produced 3-4 ng/5x10⁵ cells/24 hours after infection at an MOI = 1. Production was slightly lower in the D54MG and U251MG cell lines, at 1.8 and 0.8 ng/5x10⁵ cells/24 hours. Such levels are physiologically relevant and have been shown to produce anti-tumor responses in other models (Toda et al. (1998) *J. Immunol.* **160**, 4457-4464; Zitvogel et al. (1994) *Hum. Gene Ther.* **5**, 1493-1506).

Table 1

IL-12 production* by M002 in normal and tumor cell lines

cytokine production (pg/ml/24 h)			
Vero	D54MG	U251MG	Neuro2A
3400	1780	820	3240

*Values indicated represent only mIL-12 heterodimers.

Growth of wild-type and recombinant viruses in tumor cell lines.

Before repairing the tk gene to create M002, Applicants first established the replication competence of our tk(-) IL-12 expressing HSV (M001) as compared with wild-type "F" or the backbone virus R3659, in the human glioma cell lines D54MG and U251MG. As indicated in Figure 3, M001 replicated as well as R3659 in both glioma cell lines, and as well as the wild-type "F" strain in D54MG. This confirmed that replication competence of the IL-12 expressing virus remained intact and would be suitable for comparisons with other cytokine-expressing or parent viruses.

Viruses containing mutations or deletions within the $\gamma_134.5$ locus have previously been shown to have a direct cytolytic effect on D54MG and U251MG (Andreansky et al. (1997) *Cancer Res.* **57**, 1502-1509). Applicants quantitatively measured the cytolytic activity of M002 on Neuro2A cells, as well as D54MG and U251MG, by alamarBlue™ assay and compared the results with cytolytic activity of the backbone virus, R3659. As shown in Table 2, the cytolytic activity of M002 was slightly higher than R3659 in all cell lines tested. Thus, this virus is at least as cytotoxic in both human glioma cells and in murine Neuro2A cells as its parent virus, and may even have a slight growth advantage.

Table 2

Viral cytotoxicity of tumor cell lines

Cells	Tumor/Cell Origin	R3659 pfu/TD ₅₀	M002.29 pfu/TD ₅₀	M002.211 pfu/TD ₅₀
U251MG	GBM	1.9	1	1.1
D54MG	GBM	14.4	1.6	7.8
Neuro2A	Neuroblastoma	3	2.6	5.6

Values were obtained 3 days after virus infection, and 3 hour incubation with alamarBlue™ dye.

A syngeneic model for neuroblastoma. The GL-261 cell line is a murine glioma line derived from C57BL/6 mice, and are relatively resistant to infection by HSV-1 (Lopez (1975) *Nature* 258, 152-153). Thus, this syngeneic model is not the ideal system for evaluating the therapeutic potential of Applicants' recombinant cytokine-expressing HSV, which replicate much more efficiently in human cells than in GL-261 cells. Therefore, Applicants tested their cytokine-expressing viruses in a syngeneic model using a murine strain that would be more susceptible to HSV infection. Strain A/J mice were utilized due to their known sensitivity to HSV-1 (Lopez (1975) *Nature* 258, 152-153). There are currently no syngeneic glioma models in A/J mice. However, Neuro2A cells are a neuroblastoma cell line originally derived from A/J mice. Neuro2A tumors were established in brains of A/J mice to be evaluated as a syngeneic brain tumor model system in a more sensitive murine strain. To determine optimal tumor cell dose for evaluating M002 in these tumors in vivo, 1×10^3 , 10^4 or 10^5 cells were stereotactically introduced into A/J strain mice as described in Materials and Methods, and followed to determine median survival rates for each dose. A dose-response effect was defined for

survival, which ranged from 14 to 25 days. Based on this study, Applicants elected to inoculate between 5×10^4 and 1×10^5 cells to produce a median survival of three weeks from tumor induction in order to facilitate a rapid and stringent evaluation of the survival effects of the therapeutic viruses.

5 *Neurovirulence.* Previous studies with G207, a genetically-engineered HSV-1 currently in human trials for the treatment of malignant glioma, have shown no neurovirulence in this assay at doses of 10^7 pfu. Thus, the maximum tolerated dose was determined (pfu/LD₅₀) for both clones of Applicants' IL-12 expressing virus, M002.29 and M002.211. For clone 211, up to 2×10^7 pfu of
10 virus could be directly injected without adverse effects, whereas the maximum tolerated dose of clone 29 was 5×10^6 pfu (data not shown). Since clone 211 appeared to be the safer of the two, this virus was tested for experimental therapy of Neuro2A tumors, and is referred to herein as "M002."

15 *Survival of A/J strain mice with intracerebral Neuro-2A neuroblastomas treated with M002.* To evaluate the sensitivity of Neuro2A tumors to HSV infection in A/J strain mice, 1×10^4 tumor cells were injected intracranially into A/J female mice followed five days later by intratumoral injection of 1×10^7 pfu (in 5 μ l) of either R3659 or M002 (mIL-12). As a control, 5 μ l of the diluent were also injected. Data shown in Figure 4
20 represent a composite of three experiments, the median survival post-tumor induction in mice injected with diluent only was 19.8 days, and all animals were dead by day 34. In contrast, mice with M002-injected tumors had a significant increase on median survival of 50.5 days ($p = 0.00023$), calculated using the log-rank test. Mice that received an intratumoral injection of R3659

had a median survival (19.5 days) that was not significantly different ($p = 0.556$) from vehicle-treated mice. All survivors were sacrificed at 59 days and their brains examined histologically but there was no evidence of tumor.

Immunohistologic identification of inflammatory cell infiltrates.

5 Intratumoral injection of the parent $\gamma_134.5^-$ HSV, R3659, induced a mild but discernible immune-related inflammatory response characterized principally by macrophages and $CD4^+$ T cells with a few $CD8^+$ T cells. These inflammatory cells were scattered throughout the tumor mass with occasional foci predominated by macrophages or $CD4^+$ T cells. In contrast, injection of M002
10 elicited a pronounced influx of macrophages and $CD4^+$ T cells with a significant increase in $CD8^+$ T cells as well. Inflammatory responses were maximal around days 5-6 and had begun to regress by day 7 after viral injection.

Genetically engineered, neuroattenuated herpes simplex viruses (HSV)
15 expressing various cytokines can improve survival in the treatment of experimental brain tumors. These attenuated viruses have both copies of $\gamma_134.5$ deleted. Recently, Applicants demonstrated increased survival of C57BL/6 mice bearing syngeneic GL-261 gliomas when treated with an engineered HSV expressing IL-4, a potent mediator of T_H-2 type responses, as
20 compared to treatment with the parent construct ($\gamma_134.5^-$) alone or a virus expressing IL-10 (*Gene Therapy* 5: 121, 1998). The construction of a conditionally replication competent mutant expressing both subunits of murine IL-12 (M002), and its evaluation in a syngeneic neuroblastoma murine model is described. IL-12 induces a T_H-1 type response, which may induce more

5 durable anti-tumor effects. *In vitro* studies demonstrated that, when infected with M002, both Vero cells and Neuro2A neuroblastoma cells produced physiologically relevant levels of IL-12 heterodimers, as determined by ELISA. M002 was cytotoxic for human glioma cell lines U251MG and D54MG. Neurotoxicity studies, as defined by pfu/LD₅₀, performed in HSV-1 sensitive A/J strain mice revealed that M002 was not toxic even at high doses. When evaluated in an intracranial syngeneic neuroblastoma murine model, median survival of M002-treated animals was significantly longer than animals treated with R3659, the parent $\gamma_134.5^-$ mutant lacking any cytokine gene insert.

10 Immunohistochemical analysis of M002-treated tumors revealed a pronounced influx of CD4⁺ T cells and macrophages, as well as CD8⁺ cells when compared with R3659-treated tumors. M002 produced a survival benefit via oncolytic effects combined with T_H-1 mediated immunologic effects.

15 In view of the teaching presented herein, other modifications and variations of the present invention will readily be apparent to those of skill in the art. The discussion and description are illustrative of some embodiments of the present invention, but are not meant to be limitations on the practice thereof. It is the following claims, including all equivalents, which define the scope of the invention.

20 Any patents or publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

Claims

1 1. A method for treating a subject suffering from cancer, said
2 method comprising the step of:

3 administering to a subject a therapeutically effective amount of a herpes
4 simplex virus (HSV) comprising a nucleic acid sequence encoding for an agent
5 selected from the group consisting of interleukin-12, granulocyte macrophage
6 colony stimulating factor, and cytosine deaminase such that an anti-cancer
7 response is induced in the subject.

1 2. A method according to claim 1, wherein said administering step
2 comprises intratumorally disposing the HSV into the subject.

1 3. A method according to claim 1, wherein the HSV vector is
2 substantially aneurovirulent.

1 4. A method according to claim 3, wherein the HSV vector is
2 replication competent.

1 5. A method according to claim 3, wherein the HSV vector
2 comprises a deletion of the $\gamma_134.5$ gene.

1 6. A method according to claim 5, wherein IL-12 genes are
2 inserted within the $\gamma_134.5$ gene deletion.

1 7. A method according to claim 6, wherein the IL-12 genes
2 comprise subunits p35 and p40 separated by an IRES sequence.

1 8. A method according to claim 7, wherein said IL-12 encoding
2 nucleic acid sequence bicistronically expresses the p35 and p40 subunits to
3 produce self-assembling, heterodimeric IL-12 in the HSV vector.

1 9. An anti-tumor pharmaceutical composition comprising a herpes
2 simplex virus (HSV) vector comprising a nucleic acid sequence encoding for a
3 compound selected from the group consisting of IL-12, GM-CSF, and CD
4 operatively linked to a promoter, and a pharmaceutically acceptable carrier.

1 10. A pharmaceutical composition according to claim 9, wherein
2 said HSV vector is substantially aneurovirulent.

1 11. A pharmaceutical composition according to claim 9, wherein
2 said HSV vector is replication competent.

1 12. A pharmaceutical composition according to claim 9, wherein
2 said HSV vector has been transformed with an expression cassette comprising
3 nucleic acid sequences encoding for the p40 and p35 of IL-12, said subunits
4 being separated from each other by an IRES encoding sequence.

1 13. A pharmaceutical composition according to claim 12, wherein
2 said HSV vector includes a deletion of the $\gamma_134.5$ gene.

1 14. A pharmaceutical composition according to claim 9, wherein the
2 expression of the nucleic acid sequence encoding for IL-12 results in
3 constitutive production of IL-12 in vivo.

1 15. A pharmaceutical composition according to claim 9 which has
2 been formulated for injection.




FIGURE 1




FIGURE 2

3/7




FIGURE 3




FIGURE 4






FIGURE 5



Both copies of the $\gamma_134.5$ gene (located within the inverted repeat sequences a, a') have been replaced with the mGM-CSF insert. The background is HSV-1 "F" strain.

FIGURE 6



Both copies of the $\gamma_1 34.5$ gene (located within the inverted repeat sequences a, a') have been replaced with the CD insert. The background is HSV-1 "F" strain. The CD insert was obtained from the vector pCD2, obtained from the American Type Culture Collection (ATCC), catalog number 40999.

References for CD insert:

Biotechniques 7: 980-990, 1989
U.S. Pat. 5,358,866 October 25, 1994

FIGURE 7

Docket No.
UAB-16102/22

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

HERPES SIMPLEX VIRUS EXPRESSING FOREIGN GENES AND METHOD FOR TREATING CANCERS THEREWITH

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 8 JUNE 2000 as United States Application No. or PCT International Application Number PCT/US00/40165

and was amended on 1 OCT. 2001

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

<u>60/138,173</u>	<u>8 JUNE 1999</u>
(Application Serial No.)	(Filing Date)
 <u>60/144,314</u>	 <u>16 JULY 1999</u>
(Application Serial No.)	(Filing Date)
 <u> </u>	 <u> </u>
(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

<u>PCT/US00/40165</u>	<u>8 JUNE 2000</u>	<u>PENDING</u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)
 <u> </u>	 <u> </u>	 <u> </u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)
 <u> </u>	 <u> </u>	 <u> </u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Ernest I. Gifford, 20,644
 Allen M. Krass, 18,277
 Irvin L. Groh, 17,505
 Douglas W. Sprinkle, 27,394
 Thomas E. Anderson, 31,318
 Ronald W. Citkowski, 31,005
 Judith M. Riley, 31,561
 Douglas J. McEvoy, 34,385

Ellen S. Cogen, 38,109
 John G. Posa, 37,424
 Roberta J. Morris, 33,196
 Avery N. Goldstein, 39,204
 Douglas L. Wathen, 41,369
 Mark D. Schneider, 43,906
 Beverly M. Bunting, 36,072

Send Correspondence to: Ellen S. Cogen
 Gifford, Krass, Groh, Sprinkle, Anderson & Citkowski, P.C.
 280 N. Old Woodward Avenue, Suite 400
 Birmingham, MI 48009-5394

Direct Telephone Calls to: (name and telephone number)
 Ellen Cogen at (248) 647-6000

Full name of sole or first inventor

Richard J. Whitley

Sole or first inventor's signature

Richard J. Whitley

Date

1-3-02

Residence

Birmingham, Alabama

Al.

Citizenship

US

Post Office Address

216 Shades Crest Circle

Birmingham, AL 35216

Full name of second inventor, if any

James MacDowell Markert

Second inventor's signature

Residence

Birmingham, Alabama

Al.

Citizenship

US

Post Office Address

4416 Clairmont Avenue

Birmingham, AL 35222

Date

1-4-02

1-4-02

3-00

Full name of third inventor, if any George Yancey Gillespie	
Third inventor's signature <i>George Yancey Gillespie</i>	Date <i>01/04/02</i>
Residence Birmingham, Alabama	
Citizenship US	
Post Office Address 4149 Cliff Road	
Birmingham, AL 35222	

4-00


Full name of fourth inventor, if any Jacqueline Ness Parker	
Fourth inventor's signature <i>Jacqueline Ness Parker</i>	Date <i>01/04/02</i>
Residence Birmingham, Alabama	
Citizenship US	
Post Office Address 2317 Misty Ridge Circle	
Birmingham, AL 35226	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Scanned copy is best available. FIG. 5-

IS/are too dark

20112012 21660001